Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data

Eloxx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.84

Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.
Cash and equivalents $56.7M at June 30, 2021, expected to fund operations into Q1 2023.
ELX-02 Phase 2 CF monotherapy data on track for Q4 2021; combination arm with ivacaftor to start by end of 2021.
ZKN-013 nominated as lead candidate for RDEB/JEB; IND-enabling GLP studies expected by end of 2021.
Received up to $2.6M award from Cystic Fibrosis Foundation for oral ribosome modulating agents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.